Erythropoietin Reduces Death and Neurodevelopmental Impairment in Neonatal Hypoxic-Ischemic Encephalopathy
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Erythropoietin (EPO) is a promising neuroprotective drug. We investigated whether EPO has beneficial effects on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy (HIE). Methods: We retrospectively reviewed the data of 56 infants with HIE born at or after 35 weeks of gestation who were admitted to Inha University Hospital between 2012 and 2021. Patients were divided into two groups based on EPO use and compared. In the EPO group, patients were administered 1,000 U/kg of EPO on days 1, 2, 3, 5, and 7, starting within 24 hours after birth. The primary outcome was death or neurodevelopmental impairment (NDI) at the age of 12 months. Results: EPO was administered to 38 infants, and 18 did not receive EPO. Only 37.5% of patients with HIE (21/56) and 60% of patients with moderate-to-severe HIE (21/35) received therapeutic hypothermia. Among all patients with HIE, death or NDI (21.1 % vs. 50.0%; odds ratio [OR], 0.09; 95% confidence interval [CI], 0.01 to 0.78; P=0.029) and brain injury on imaging (42.1% vs. 83.3%; OR, 0.16; 95% CI, 0.03 to 0.92; P=0.040) were significantly lower in the EPO group than in the control group. Among patients with moderate-to-severe HIE, brain injury on imaging (54.2% vs. 90.9%; OR, 0.04; 95% CI, 0.002 to 0.700; P=0.027) was significantly lower in the EPO group than in the control group. Conclusion: EPO administration significantly reduced mortality and NDI in infants with HIE. EPO can be considered an adjunctive therapeutic agent for neonatal HIE.
Abstract
Purpose: Erythropoietin (EPO) is a promising neuroprotective drug. We investigated whether EPO has beneficial effects on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy (HIE). Methods: We retrospectively reviewed the data of 56 infants with HIE born at or after 35 weeks of gestation who were admitted to Inha University Hospital between 2012 and 2021. Patients were divided into two groups based on EPO use and compared. In the EPO group, patients were administered 1,000 U/kg of EPO on days 1, 2, 3, 5, and 7, starting within 24 hours after birth. The primary outcome was death or neurodevelopmental impairment (NDI) at the age of 12 months. Results: EPO was administered to 38 infants, and 18 did not receive EPO. Only 37.5% of patients with HIE (21/56) and 60% of patients with moderate-to-severe HIE (21/35) received therapeutic hypothermia. Among all patients with HIE, death or NDI (21.1 % vs. 50.0%; odds ratio [OR], 0.09; 95% confidence interval [CI], 0.01 to 0.78; P=0.029) and brain injury on imaging (42.1% vs. 83.3%; OR, 0.16; 95% CI, 0.03 to 0.92; P=0.040) were significantly lower in the EPO group than in the control group. Among patients with moderate-to-severe HIE, brain injury on imaging (54.2% vs. 90.9%; OR, 0.04; 95% CI, 0.002 to 0.700; P=0.027) was significantly lower in the EPO group than in the control group. Conclusion: EPO administration significantly reduced mortality and NDI in infants with HIE. EPO can be considered an adjunctive therapeutic agent for neonatal HIE.
참고문헌 (34)
- Perin J, "Global, regional, and national causes of under-5 mortality in 2000-19: an updated systematic analysis with implications for the Sustainable Development Goals", Lancet Child Adolesc Health, 6, pp.106~115 (2022)
- Martinello K, "Management and investigation of neonatal encephalopathy : 2017 update", Arch Dis Child Fetal Neonatal Ed, 102, pp.F346~F358 (2017)
- Tagin MA, "Hypothermia for neonatal hypoxic ischemic encephalopathy : an updated systematic review and meta-analysis", Arch Pediatr Adolesc Med, 166, pp.558~566 (2012)
- 성인경, "Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy in Newborn Infants", Neonatal medicine, 24(4), pp.145~156 (2017), 대한신생아학회
- Sugawa M, "Effects of erythropoietin on glial cell development; oligodendrocyte maturation and astrocyte proliferation", Neurosci Res, 44, pp.391~403 (2002)
- Sun Y, "Mechanisms of erythropoietin-induced brain protection in neonatal hypoxiaischemia rat model", J Cereb Blood Flow Metab, 24, pp.259~270 (2004)
- Oorschot DE, "Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: history, current status, and future research", Int J Mol Sci, 21, pp.1487~ (2020)
- Razak A, "Erythropoietin in perinatal hypoxic-ischemic encephalopathy : a systematic review and meta-analysis", J Perinat Med, 47, pp.478~489 (2019)
- Juul SE, "High-dose erythropoietin for asphyxia and encephalopathy (HEAL): a randomized controlled trial: background, aims, and study protocol", Neonatology, 113, pp.331~338 (2018)
- Mulkey SB, "Erythropoietin and brain magnetic resonance imaging findings in hypoxic-ischemic encephalopathy : volume of acute brain injury and 1-year neurodevelopmental outcome", J Pediatr, 186, pp.196~199 (2017)
- 박숙현, "미숙아의 신경발달학적 예후 향상을 위한 임상 연구: Erythropoietin과 영양학적 중재", Neonatal medicine, 24(3), pp.101~109 (2017), 대한신생아학회
- Wu YW, "High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy : a phase II trial", Pediatrics, 137, pp.e20160191~ (2016)
- Zhu C, "Erythropoietin improved neurologic outcomes in newborns with hypoxicischemic encephalopathy", Pediatrics, 124, pp.e218~e226 (2009)
- Sarnat HB, "Neonatal encephalopathy following fetal distress : a clinical and electroencephalographic study", Arch Neurol, 33, pp.696~705 (1976)
- Jacobs SE, "Selective head cooling with mild systemic hypothermia after neonatal encephalopathy : Multicentre randomised trial", J Pediatr, 147, pp.122~123 (2005)
- Hassell KJ, "New horizons for newborn brain protection : enhancing endogenous neuroprotection", Arch Dis Child Fetal Neonatal Ed, 100, pp.F541~F552 (2015)
- Linkenheimer WH, "Erythropoietin and known erythropoietic stimuli", Proc Soc Exp Biol Med, 104, pp.230~232 (1960)
- Halperin DS, "Effects of recombinant human erythropoietin in infants with the anemia of prematurity : a pilot study", J Pediatr, 116, pp.779~786 (1990)
- Ananthan A, "Clinical outcomes related to the gastrointestinal trophic effects of erythropoietin in preterm neonates : a systematic review and metaanalysis", Adv Nutr, 9, pp.238~246 (2018)
- Aher SM, "Early versus late erythropoietin for preventing red blood cell transfusion in preterm and", or low birth weight infants, 2012, pp.10, CD004865~
- Ohlsson A, "Early erythropoietin for preventing red blood cell transfusion in preterm and", or low birth weight infants, 2014, pp.4, CD004863~
- Xiong Y, "Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose", J Neurosurg, 113, pp.598~608 (2010)
- Gonzalez FF, "Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke", Stroke, 44, pp.753~758 (2013)
- Kaneko N, "Enhancement of ventricularsubventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives", Front Cell Neurosci, 7, pp.235~ (2013)
- Wang L, "Matrix metalloproteinase 2(MMP2)and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration", J Neurosci, 26, pp.5996~6003 (2006)
- Villa P, "Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives", J Cereb Blood Flow Metab, 27, pp.552~563 (2007)
- Gonzalez FF, "Erythropoietin sustains cognitive function and brain volume after neonatal stroke", Dev Neurosci, 31, pp.403~411 (2009)
- Fan X, "Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice", Pediatr Res, 69, pp.56~61 (2011)
- Elmahdy H, "Human recombinant erythropoietin in asphyxia neonatorum : pilot trial", Pediatrics, 125, pp.e1135~e1142 (2010)
- Ohls RK, "Preschool assessment of preterm infants treated with darbepoetin and erythropoietin", Pediatrics, 137, pp.e20153859~ (2016)
- Song J, "Recombinant human erythropoietin improves neurological outcomes in very preterm infants", Ann Neurol, 80, pp.24~34 (2016)
- Fischer HS, "Prophylactic early erythropoietin for neuroprotection in preterm infants : a metaanalysis", Pediatrics, 139, pp.e20164317~ (2017)
- Wu YW, "Erythropoietin for neuroprotection in neonatal encephalopathy : safety and pharmacokinetics", Pediatrics, 130, pp.683~691 (2012)
- Juul SE, "A randomized trial of erythropoietin for neuroprotection in preterm infants", N Engl J Med, 382, pp.233~243 (2020)